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Abstract 
Therapeutic delivery technology is a current area of high interest in both university and 
industrial settings. These technologies are being developed in order to deliver therapeutic 
agents, such as genes, proteins, and drugs, to patients more efficiently. Nanoscale 
delivery vehicles have proven to be useful for these applications; these vehicles may 
either be naturally produced or chemically synthesized. The physical properties of these 
nanomaterials must be characterized correctly using instrumentation that evaluates their 
size, morphology, and potential for agglomeration. These technologies represent a high-
growth economic area that fosters entrepreneurship and innovation. Because of this 
innovative spirit, research and economic interest will continue to be focused on 
therapeutic delivery technologies.  
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Therapeutic Delivery and its Economic Impact 
Introduction 
 The primary goal of modern therapeutic delivery research is to develop new ways 
to localize treatments to a region of the body. These therapies are highly popular among 
research groups focusing on diseases ranging from cancer to cardiovascular to 
gastrointestinal diseases (Serna 2018, O’Quinn 2018, Beitelshees 2017). In cancer 
research, chemotherapy is a common treatment for the elimination of tumors, but its 
effects are often not specific to the affected area. The effects of chemotherapy impact the 
whole body and is typically a painful process for those needing treatment. Localizing 
treatment can alleviate pain associated with systemic drug administration. Another 
important aspect of current drug delivery research is the design and engineering of 
controlled release mechanisms. These mechanisms prevent an excess of drug initially 
introduced to the system. Although it is typical that a majority of the drug is released 
upon administration, there is a sustained release of the remaining drug or therapeutic 
agent over-time. This controlled release allows continuous treatment to the localized 
areas. While the general principle of drug delivery remains the same, there are multiple 
designs or types of methods. 
Gene Therapy 
 Several types of therapeutic agents can be used for treatment in a drug delivery 
system. Genes, proteins, and conventional drugs may all be used for treatment; however, 
the particular use of each depends on the disease. For disease with a genetic basis, gene 
therapy techniques are utilized. Genetically based diseases are the result of a mutation in 
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the genetic code, chromosomal mutations, or alteration of chromosomal ploidy. A 
mutation in the genetic code can be defined as the alteration of a single base (NIH 2019). 
In the context of inherited disease, this mutation would not be caused externally. The 
severity of these mutations varies significantly, from no direct impact to the production of 
a nonfunctional protein (NIH 2019). Chromosomal mutations refer to alterations in 
specific chromosomal regions. In comparison to genetic code mutations, chromosomal 
mutations involve many more bases since a whole chromosomal region is being altered 
(NIH 2019). There are several types of chromosomal mutations which include inversion, 
insertion, and deletion (NIH 2019). Gene delivery is commonly used with chromosomal 
deletions (NIH, Gene Therapy 2019).  
 Chromosomal deletions are being targeted as potential gene therapy treatment 
areas. For example, Wiskott-Aldrich syndrome (WAS), a disease resulting in small 
platelet size, thrombocytopenia, and recurrent bacterial and viral infections, is caused by 
partial deletion of the WAS gene (Chandra et al 2004). In total, the WAS gene is over 
9000 bases, indicating that partial deletion involves hundreds or even thousands of bases 
(Chandra et al. 2004). To be treated using gene therapy, the deleted region of the WAS 
gene would be delivered to the cell and integrated into the cellular genome. The basis of 
these techniques is the delivery of a healthy DNA segment containing the mutated or 
missing portion of the gene. This “healthy” DNA segment is integrated into the cellular 
genome, and cellular proliferation occurs. Newly created cells do not have the mutation 
and are not defective. As cells reproduce and die, a larger percent of cells are now healthy 
and the damaged cells are gradually phased out. Gene therapy was first successfully used 
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to treat adenosine deaminase deficiency, a genetic defect in which the enzyme adenosine 
deaminase is deficient, in 1990 (NIH history). Since 1990, other diseases, such as 
hemophilia, WAS, and cancer, have been identified as potential gene therapy targets; 
however, acute lymphoblastic leukemia is the only currently FDA approved disease for 
gene therapy (Beitelshees 2017). Although gene therapies are still being explored, many 
treatments only reach clinical trial phase and are not granted FDA approval (Beitelshees 
2017). While gene therapy has great promise, issues with cellular integration have 
hindered its widespread usage. Since DNA will not be directly integrated into the genome 
when introduced to the cell, its delivery method must be designed such that cellular 
integration occurs (NIH). Nanocarriers have recently proven to be an effective method of 
gene delivery; these delivery methods will be discussed later.  
Peptide and Drug Delivery 
 This variation is a direct result of the greater breadth of protein function when 
compared to DNA. Protein functions include, but are not limited to, enzymatic, 
immunological, and transport activities. Another aspect of protein therapy that differs 
from gene therapy is the necessity of continued treatment. Since healthy proteins do not 
replicate and become incorporated into subsequent cell lines like DNA does, there must 
be continual protein application. For example, patients that require protein therapy have 
to be treated by medical professionals every few weeks to ensure sufficient protein levels. 
In this way, the protein is more similar to the case in which a traditional drug is 
administered. A key motivation of protein therapy design is cytotoxicity, for the purpose 
of eliminating tumors. Cytotoxicity is vital for the treatment of cancer and inflammatory 
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diseases (Serna et al. 2018). Although cytotoxic cancer treatment may be effective by 
reducing cancerous tissue, the side-effects of non-localized therapies are detrimental. 
Cytotoxic treatments, whether by peptide or drug, by nature are poisonous. If their effects 
are not reduced to areas of interest, such as tumors, the global effects on the body will be 
harmful (Serna et al. 2018). Several key side effects of non-localized cytotoxic therapies 
include kidney failure, cardiotoxicity, and immunosuppression (Serna et al. 2018). While 
beneficial long-term, there is a clear motivation for improvement of these treatments with 
regards to localization within the body. Targeted nanocarrier-protein complexes are 
highly promising treatment localization methods. Similarly, targeted nanoscale delivery 
vehicles are effective for drug delivery as well. The key difference between protein 
delivery and drug delivery is molecule classification. If the delivered molecule is a 
peptide, then the treatment would be considered protein therapy. Alternatively, if a non-
peptide molecule is being delivered, the method is considered drug delivery. Cytotoxic 
cancer treatments apply to traditional drug-methods as well. The type of treatment 
dictates what drug delivery method should be used. Many of these technologies are on 
the nanoscale to ensure efficient delivery; if the size of the deliverer is too big, it could be 
harmful. Based on blood lifetimes and bioavailability, the ideal size range for 
nanoparticles is between 10-200 nm; the properties of the nanoparticles are highly 
variable within this size range (Goldberg 2007). Natural and synthetic nanocarriers are 
used for therapeutic delivery. 
Nanoscale Vehicles for Therapeutic Delivery 
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 Viral vectors are effective vehicles for gene therapy, while polymeric nanocarriers 
and polymer conjugates are the most common peptide and drug delivery vehicles. 
Polymeric vehicles must be synthesized. In preparation for gene therapy, virus particles 
must be grown in culture (Warnock et al. 2006). The species used varies and is dependent 
on viral properties such as size, toxicity, and the molecular composition of the viral 
genome. The size of the virus naturally affects the amount of genetic information that can 
be integrated into the viral genome. Adenovirus (90-100nm) and adeno-associated virus 
(20 nm) integrate up to 38 kilobases (kb) and 4.8 kb of DNA, respectively (Nayerossadat 
et al. 2012). This disparity in deliverable DNA is directly related to particle size. Viral 
gene delivery vehicles utilize normal virus-host cell interactions, in which the viral 
genome and the host-cell genome are integrated (Huang et al. 2011). While this normal 
physiological action is useful, viral genome editing must be done to prevent infection 
(Huang et al. 2011). Vectors must not promote an immune response (Howarth et al. 
2009). For example, Herpes simplex virus (HSV) naturally causes cold sores or genital 
warts in humans; however, if its replicative genes are deleted or mutated, no symptoms 
occur (Berto et al. 2005). In regards to the viral genome molecular composition, viruses 
can either have genomes composed of DNA or RNA. This difference is manifested upon 
nucleic acid uptake by the host-cell. In the case of DNA viruses, the injected DNA will 
be directly inserted into the host cell genome. Alternatively, RNA-viruses, or 
retroviruses, make use of reverse-transcriptases, which convert RNA to DNA; this newly 
synthesized DNA can then be integrated into the host genome (Youngsuk et al. 2011).  
Polymeric Nanoparticles 
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 Polymeric nanoparticles are a common type of synthetic vectors, or vehicles, for 
therapeutic delivery. There are several varieties of polymeric nanoparticles. These 
nanoparticles are comprised of a polymeric core. The characteristic polymer must be 
biocompatible in order to prevent toxic side-effects; biodegradability is also an important 
nanoparticle quality. (Masood et al. 2016). If the nanoparticles were not biodegradable, 
they would not be able to be broken down. This buildup of residual material has the 
potential to cause side-effects even though the polymer itself may not be intrinsically 
harmful. Several biocompatible and biodegradable polymers used as nanoparticle cores 
are poly(lactic-co-glycolic acid) (PLGA), poly(aspartic acid), and polylactic acid (PLA) 
(Masood 2016, Crucho et al. 2017). PLGA is currently the only FDA approved polymer 
for drug delivery purposes (Elsabahy 2012). In addition to toxicity concerns, drug-
polymer compatibility must be considered when selecting the polymer comprising the 
therapeutic vehicle. For example, cancer drugs such as paclitaxel and doxorubicin are not 
water soluble. If these drugs were desired to be used via drug delivery vehicles, a 
hydrophobic polymer core would be optimal; for this reason, PLGA and PLA 
nanocarriers are currently being investigated as deliverers of paclitaxel and doxorubicin 
(Masood 2016). Also, polymeric nanoparticles act as nucleic acid or drug protection. 
Nucleic acids are easily degraded, so their protection is necessary for treatment action 
(Amreddy et al. 2017). Premature degradation or release inhibits therapeutic 
effectiveness, especially when targeting is crucial to treatment rationale (Amreddy et al. 
2017). A targeted cytotoxic drug, such as PLGA-paclitaxel nanoparticles, that does not 
have a protective vehicle should not be any less detrimental to the patient than using an 
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uncomplexed form. Modification of PLGA and PLA nanoparticles is necessary to add 
durability as well as to water solubilize them.  
 Nanoparticles composed of PLGA or PLA need to be altered so they will be 
hydrophilic; an unmodified, hydrophobic nanoparticle will not mix well in the body’s 
aqueous environment. This problem is solved by attaching a hydrophilic polymer to the 
nanoparticle exterior (Elsabahy 2012). Polyethylene glycol (PEG) is currently the only 
FDA-approved polymer for this alteration (Elsabahy 2012). PEG is an effective polymer 
for this role because of the single hydroxyl groups at each terminal. These hydroxyl 
groups promote interaction with both the body’s aqueous environment and 
functionalization for polymerization with PLGA or PLA. PEG essentially acts as a 
coating for polymeric nanoparticles, offering protection and enhanced pharmacological 
properties. Nanoparticles with a PEG exterior have a hydrated radius due to hydrogen 
bonding between PEG and water molecules; this hydration prevents premature 
degradation by enzymes (Makadia et al. 2011). PEG must be functionalized in order to 
polymerize with PLGA or PLA. For PLGA-PEG copolymer synthesis, PEG may be 
carboxylated and added to an N-hydroxysuccinimide derivatized PLGA (Cheng et al. 
2006). Another older method causes PEGylation of PLGA by first polymerizing PEG-
PLA and then subsequently PEG-PLGA by opening the cyclic lactide and glycolide (Li et 
al. 2001). These modifications are preceded by synthesis of the nanoparticle core. 
Synthetic Methods of Polymeric Nanoparticles 
 Emulsion methods are the most commonly used polymeric nanoparticle synthetic 
methods. They can be classified as either single or double emulsion. An emulsion 
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consists of droplets suspended in a solvent; the droplets and solvent are immiscible. 
Single emulsions are classified as water in oil (w/o) or oil in water (o/w) emulsions. A 
w/o emulsion is one that has water soluble droplets suspended in a hydrophobic solvent, 
while o/w has hydrophobic components suspended in an aqueous or polar environment 
(Rao 2011). The term “water” in the context of emulsions specifies a hydrophilic 
environment and does not necessarily imply the presence of water. A surfactant, or 
stabilizer, is present in any emulsion in order to prevent particle aggregation. Common 
surfactants include poly(vinyl) alcohol (PVA), poly(ethylene) oxide (PEO), and 
polyvinyl pyrrolidone (PVP) (Heinz 2017). The solvent evaporation method is an older, 
but commonly used o/w emulsion method to synthesize polymeric nanoparticles. In this 
method, a hydrophobic polymer is dissolved in a solvent that is miscible with water; this 
solution is mixed with water and surfactant (Murakami 1999). As these two solutions 
mix, the water miscible solvent mixes with the water; however, the hydrophobic polymer 
cannot, and nanoparticle formation is promoted (Murakami 1999). After this dispersion, 
the polymer solvent is evaporated and the particles are subsequently resuspended 
(Murakami 1999). These nanoparticles are then dried for storage. Lipid nanoparticles 
have also been prepared using a solvent evaporation method (Trotta et al. 2003). In order 
to load therapeutics onto the nanoparticles, the desired therapeutic is added to the 
polymer or hydrophilic solution, depending on drug polarity. A double emulsion version 
(w/o/w or o/w/o) of the solvent evaporation method is similar to the single emulsion 
method; however, an additional dispersion step is done. Once the initial w/o or o/w 
dispersion is done, it is dispersed in a solution of the opposite phase. Although this 
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additional step may seem inconsequential, it affects the drug encapsulation properties of 
the nanoparticles (Iqbal 2015). Single emulsion and double emulsions differ in the 
properties of the synthesized nanoparticles, properties which include their ability to 
encapsulate hydrophobic or hydrophilic drugs and nanoparticle polydispersity. 
Hydrophobic drugs can easily and effectively be loaded into nanoparticles using o/w or 
w/o single emulsions (Ramalho 2016). This method does not, however, encapsulate 
hydrophilic drugs.  
 Nanoprecipitation is a faster and simpler way to form nanoparticles than emulsion 
and other methods. A hydrophobic polymer is dissolved in a water-miscible solvent, 
which is often acetonitrile (Iqbal 2015, Fessi 1989). This solution is then mixed with 
water, and nanoparticles are formed; the synthesized nanoparticles are collected once the 
solvent is evaporated (Fessi 1989, Iqbal 2015). This method, first discovered in 1989, 
resembles the solvent evaporation method; however, nanoprecipitation is only efficient 
for hydrophobic drug encapsulation, while traditional emulsion methods may be used to 
encapsulate hydrophilic or hydrophobic drugs (Iqbal 2015).  
Nanoparticle Targeting 
 Although treatment using nanoparticles is useful because of their sustained release 
properties, an important motivation for using them is their targeting properties. Targeting 
these nanoparticles can be done through ligand attachment (Duskey et al. 2014).  
 A ligand is added to the nanoparticle surface to localize a drug’s effect. Ligands 
are designed specifically to target certain disease indicators. Cancer biomarkers represent 
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a large area of ligand usage (Bahrami et al. 2017). Antibodies are common nanoparticle 
targeting ligands for cancer cells (Bahrami 2017, Friedman 2013). Antigens, which are 
proteinaceous cellular recognition sites, are present on all cell membranes and act as 
antibody binding sites. These antigens are cell-type specific; this specificity enables 
effective targeting by a corresponding antibody. Tumor-specific antigens present due to 
cancer-associated genetic mutations (Escors 2014). Tyrosinase-related protein 1 (TRP 1) 
is a cell surface antigen characteristic of cutaneous melanomas; they do not express 
regularly with other types of cancer (Ghanem 2011). TRP 1 is currently a candidate for 
antibody targeted therapeutic delivery (Ghanem 2011). Non-small-cell lung cancer, 
another common cancer type, also has potential for antibody targeted therapy. In this type 
of lung cancer, epidermal growth factor receptor (EGFR) manifests itself in cancerous 
lung tissue (Karra et al. 2013). One study used EGFR targeted, paclitaxel loaded 
nanoparticles to specifically kill tumorous lung cells (Karra et al. 2013). This study also 
revealed improved cytotoxicity towards cancerous tissue using antibody targeted 
nanoparticles (Karra et al. 2013). While specific localization is a reason for this improved 
cytotoxicity, enhanced permeability and retention (EPR) may be an additional factor. 
EPR is a passive targeting mechanism in which nanoparticles agglomerate in bodily 
regions near tumors (Carter et al. 2016). Specific targeting, in conjunction with EPR, 
would logically increase delivery of cytotoxic drug, such as paclitaxel, as well as 
maintaining cell-localization. Antibody ligands are popular because of their widespread 
availability (Friedman et al. 2013).  Large scale commercialization is due to already 
existing antibody use in common molecular research techniques. Antibody targeting 
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ligands are widely used for cancer treatment and are also being further investigated 
(Friedman 2013).  
Pharmacodynamics and Pharmacokinetics of Therapeutic Delivery Vehicles 
 While these methods of drug delivery are all used because of their size, several 
properties, such as biocompatibility, biodegradability, encapsulation efficiency, and drug-
release kinetics, have made some methods more favorable. These properties comprise the 
pharmacodynamic and pharmacokinetic properties of therapeutic nanoparticles. 
Pharmacodynamics is the study of how the drug is altered by the body, whereas the 
pharmacokinetics of a drug are its effects on the body (Shargel et al. 2012). These two 
principles are material dependent, as different compounds naturally cause diverse body-
drug interactions. Although these properties will be described briefly, further reading is 
recommended for deeper understanding 
 Biocompatible compounds are not toxic to the body. Biodegradable compounds 
are those the body can break down. Nanoparticles for therapeutic use should be both 
biocompatible and biodegradable. PLGA and PLA are two compounds used because of 
their biocompatibility and biodegradability. In aqueous environments, these polymers are 
degraded; the products formed are lactic acid and glycolic acid or just lactic acid for 
PLGA and PLA, respectively (Mahaptro et al. 2011). The degradation products are 
natural metabolites, so they are not inherently toxic (Mahaptro et al. 2011). Many 
genome-edited viral vectors satisfy these requirements; however, there are still health and 
safety concerns.  
THERAPEUTIC DELIVERY 
 
15 
 Besides targeted therapy, a prime motivation of nanoscale drug delivery is 
enhanced drug-release rates. Nanocarriers release their drugs over time; this sustained 
release is particularly important for cancer drug administration (Iqbal et al. 2015). 
Continual release prevents a large influx of cytotoxic cancer drugs and diminishes 
harmful chemotherapy side-effects. Dialysis is the key method for evaluating 
nanoparticle drug-release kinetics (D’Souza, 2014). In dialysis, the sample is injected into 
dialysis tubing or a dialysis cassette; release media is added, and the prepared sample is 
placed into a container of release media (D’Souza, 2014). The tubing or cassette 
membrane is selectively permeable by size (Iqbal 2015). Because of this size 
permeability, molecules below the size cutoff are free to diffuse across the membrane 
into the outer release media. An ideal in vitro release media would be a buffer that 
mimics biological conditions, such as phosphate buffered saline at pH 7.4 (PBS) 
(D’Souza 2014). Aliquots of the outer release media should be taken to evaluate the 
amount of released drug; this quantity can be measured spectrophotometrically or 
fluorometrically using a drug-compatible dye. Encapsulation efficiency can be 
extrapolated from the drug-release kinetics profile. Encapsulation efficiency is the 
percentage of drug loaded onto a nanoparticle (Wallace et al. 2012). A good 
encapsulation efficiency is vital to the ability of a nanoparticle to deliver sufficient drug 
amount. In addition to the aforementioned biologically relevant characteristics of 
therapeutic nanoparticles, characterization of their physical properties is important to 
determine their effectiveness.   
Characterization  
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 Instrumentation for nanoparticle characterization is vital for effective therapeutic 
effect. The nanoparticles must be within a certain size and stability range; the zeta 
potential of a nanoparticle is indicative of its stability. Therapeutically effective 
nanoparticles have a size range between 70-200 nm (Goldberg et al. 2007). Nanoparticles 
have a surface charge; because they are charged, there is a charged layer surrounding 
them called the Stern layer (Xu 2007). For example, a negatively charged nanoparticle 
would have a layer of positively charged ions surrounding it. The potential between this 
layer and the external medium is the zeta potential (Xu 2007). A nanoparticle suspension 
having a zeta potential greater than or about ±20 mV are stable enough to be used for 
drug delivery applications; the larger the zeta potential, the more stable the nanoparticle 
suspension is (Honary et al. 2013). Zeta potentials below ±10 mV promote nanoparticle 
aggregation because the electrostatic attraction between one nanoparticle’s surface charge 
and another’s Stern layer is greater than the repulsion due to the surface charge of each 
nanoparticle (Honary et al. 2013). Zeta potential is dependent on pH, ionic strength, and 
concentration; it is a size independent property (Bhattacharjee 2016). Each nanoparticle 
has an isoelectric point when pH is varied, a point where aggregation is favored; zeta 
potential is directly and indirectly related to concentration and ionic strength, respectively 
(Bhattacharjee 2016). Size measurements are typically done by Dynamic Light Scattering 
(DLS), but Nanoparticle Tracking Analysis (NTA) is another effective method. Stability 
measurements can be done by electrophoretic light scattering (ELS) or phase analysis 
light scattering (PALS). If an electric field is applied, NTA also measures zeta potential. 
The theory behind these techniques is similar in their analysis of scattered light, but they 
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differ in how they process the information. Zeta potential measurements require the 
Smoluchowski-Einstein equation, which relates a particle’s velocity in solution when an 
electric field is applied. Particle shape and morphology can be evaluated using 
transmission electron microscopy (TEM) (Slocik et al. 2005). Particle size is measured 
through examining each particle’s Brownian motion through a diffusional coefficient 
calculated by the Stokes-Einstein equation.  
Dynamic Light Scattering 
 Dynamic light scattering (DLS) measures the average nanoparticle size based on 
its diffusion due to Brownian motion and the resultant elastic light scattering in a 
colloidal suspension. Doppler broadening of the scattered light occurs because of the 
particles’ characteristic Brownian motion. This diffusion is only possible if nanoparticles 
are dispersed since they have an intrinsic tendency to aggregate (Xu 2007). Its 
hydrodynamic radius is then extrapolated from the Stokes-Einstein equation (Ito et al. 
2004). 
 
 Stokes-Einstein Equation where D is diffusion coefficient, kB is Boltzmann’s 
constant, T is temperature, ƞ is solution viscosity, and rh is particle radius (Schulze et al. 
2014).  
The diffusion coefficient measured by this method is characteristic of the whole 
suspension, rather than that of an individual nanoparticle; the average nanoparticle 
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hydrodynamic radius for the entire suspension is calculated (Xu 2007). Due to the 
tendency of the nanoparticle to aggregate, solution viscosity must also be minimized to 
increase the diffusion coefficient. A particle’s hydrodynamic radius is its theoretical size; 
its true size is impossible to measure due to limitations relating to its shape and matrix 
interactions; this theoretical size assumes the globular particle would have the same 
velocity as a spherical particle of the same size (Malvern). A particle size distribution is 
generated and exhibits broadening because of such limitations. Ensemble averaging must 
be applied to this data to produce an average size estimate (Ito et al. 2004). When 
applied, ensemble averaging generates a better signal to noise ratio as well as a smoother 
curve. For non-spherical particles, such as nanorods, DLS produces a bimodal size 
distribution; this bimodal distribution occurs because of the detected translational and 
rotational movement of the nanorod (Liu et al. 2012). While it is important to note the 
differences between spherical and non-spherical nanoparticle distributions, DLS for 
spherical particles will be considered here.  
 Instrumentation for DLS instruments contain a laser, sample cell, and a detector. 
The laser used in DLS acts as the light source. This laser has historically been a gas laser, 
but many instrument manufacturers are switching to laser diodes, which are more 
powerful, 30 mW compared to 10 mW, and cheaper (Xu 2007). Laser diodes also have 
several operating wavelengths, accommodating for a potentially necessary change in 
source intensity or fluorometric nanoparticle analysis. Sample cells are typically cuvettes. 
Because of solution viscosity considerations, the sample should be mixed homogeneously 
before placement into the sample cell. A photomultiplier tube is the most commonly used 
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detector. It is necessary to use a photomultiplier tube because weak scattering signals 
need to be amplified to attain a sufficient signal to noise ratio. Detectors for DLS must be 
at a fixed angle to the source and sample to ensure that scattered light can be detected 
over a wide range of angles since scattering occurs at many angles (Nemoto et al. 1981). 
While sizing is accomplished by DLS, zeta potential measurements are an indication of 
nanoparticle stability.  
Zeta Potential 
 Nanoparticles are charged molecules and have oppositely charged ions, or 
counter-ions associated with them. These counter-ions have electrostatic interactions with 
the surrounding solution, forming what is known as the shear plane. The potential arising 
from these interactions is the zeta potential (Cho et al. 2012). Zeta potential is a measure 
of nanoparticle stability. The most common technique to measure zeta potential is 
electrophoretic light scattering (ELS), also called phase analysis light scattering. ELS 
probes the surface charge response when an external electrical field is applied to the 
suspension (Zhang et al. 2008). Similarly to DLS, there is a frequency shift due to 
nanoparticle motion, which leads to Doppler broadening (Ito et al. 2004). Nanoparticle 
motion during ELS is not Brownian motion, as in DLS, because it is affected by the 
electrical field. Electrophoretic mobility of the particle is measured, and its zeta potential 
is extrapolated from the Smoluchowski Equation: 
v=ζ (ɛE/ƞ) 
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where v is electrophoretic velocity, ƞ is solvent viscosity, ɛ is electrical permittivity, or 
dielectric constant, of solution, and electric field strength (Zhang et al. 2008). The ionic 
strength of the solvent is an important consideration when evaluating zeta potential; the 
relative strength of ions in the solution affects how and to what extent they interact with 
nanoparticles (Coday et al. 2014). The solution’s pH also affects the nanoparticles and 
their counter-ions (Ito et al. 2004). This association is directly proportional to the 
electrophoretic velocity of the nanoparticles. Electrical permittivity is the resistance of 
the solution when an electric field is applied. It is measured as a ratio of solution field 
strength to the initial electric field strength. Viscosity must be minimized for the same 
reason as it is for DLS. For biological applicability, nanoparticles must be negatively 
charged. Negatively charged nanoparticles will have positive counter-ions and will then 
interact with negatively charged molecules. This positive charge is important in 
biological systems because cell membranes carry a net negative charge (Cho et al. 2012). 
Repulsion would occur between positively charged nanoparticles not because of its 
inherent charge, but because of the counter-ions associated with it. Much of the 
instrumentation for ELS has similarities with DLS instrumentation.  
  A laser source is oriented perpendicularly to the sample cell and detector instead 
of just the detector like DLS. Since the source is orthogonal to the sample cell, mirrors 
must be utilized (Kaszuba et al. 2010). While the sample cell and detector are 
perpendicular to the source, they are not in line with each other to account for scattered 
light from the suspension; an optimal angle between the sample and detector is 13° 
(Kaszuba et al. 2010). An electrode is used to apply the external electrical field. A 
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photomultiplier tube is also used in ELS. The Malvern Nanosight NS500 can measure 
nanoparticle size and zeta potential using nanoparticle tracking analysis (NTA) and ELS.   
Nanoparticle Tracking Analysis 
 NTA is similar to DLS. It uses light scattering to analyze particle size in a 
suspension.  While DLS analyses nanoparticles as a total distribution, NTA examines 
individual particle size; this individual particle sizing is possible as a result of a 
microscope detector (Malvern 2015). Even though NTA can observe individual particle 
sizes, a distribution is still generated. The microscope images the colloid suspension in 
real time and the particles can be visualized based on their scattered light. One of the 
main differences between NTA and DLS is the sample introduction method. Since 
particle motion is necessary for evaluation of electrophoretic mobility, the suspension is 
pumped into the sample cell. The sample colloidal system is first diluted if necessary, due 
to concentration and viscosity considerations. The solvent is allowed to flow through the 
system to eliminate potentially interfering residual materials. Water is a common solvent. 
The flow rate is controlled by a peristaltic pump that causes aspiration of the solution. A 
tube starting at the sample leads to the pump, which generates suction. After passage 
through the pump, the sample then flows through the sample cell. This sample cell is 
irradiated with a laser; the scattered light is analyzed by the microscope detector, which is 
orientated nearly perpendicularly (Malvern 2015). This nearly orthogonal orientation may 
be necessary for optimal scattering. If positioned at 90°, less scattered light would be 
detected by the microscope and measurements could contain significant error. An electric 
field is applied to this sample by electrodes (Malvern 2015). This electric field is 
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necessary to determine zeta potential. Electrophoretic velocity is measured similarly to 
that of an instrument dedicated to ELS. While NTA is an effective method of determining 
nanoparticle size and stability, DLS and ELS, when combined are more common 
methods for nanoparticle characterization. Morphological characterization is necessary to 
confirm particle shape. This type of characterization is commonly done using 
transmission electron microscopy (TEM). 
Transmission Electron Microscopy  
 TEM is similar, in theory, to standard light microscopy; however, electrons are 
used instead of visible light. Electrons are transmitted through the sample and an image is 
generated based on beam interactions with a detector; electromagnetic lenses must be 
used instead of optical lenses to detect transmitted electrons. An electron has a shorter 
wavelength than visible light, so resolution is enhanced. TEM has been shown to resolve 
platinum nanoparticles 2 nm in diameter (House et al. 2016). While nanoparticles of this 
size and composition are not commonly used for biomedical applications, the resolving 
power demonstrates the usefulness of the TEM for nanoscale imaging. Currently, 
benchtop TEM’s, or low-voltage electron microscopes (LVEM) are sometimes used to 
obtain a similar result as TEM (Bell et al. 2014). LVEM’s have lower resolving power, 
but typically can be operated on a much shorter timescale than a TEM. LVEM are also 
much cheaper and smaller than a standard TEM (Delong) TEMs are also large and 
generally take up a whole room or research space; LVEM’s offer an advantage in this 
regard as well. An image taken using a TEM or LVEM is in grayscale and resembles an 
image seen on a light microscope, as seen in Figure 1. While this picture is blurry due to 
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instrument miscalibration, it demonstrates how TEM or LVEM can be used to analyze 
nanoparticles size and morphology.  
 
Figure 1. PLGA Nanoparticles Imaged Using Low Voltage Electron Microscopy 
(LVEM). Synthesized PLGA nanoparticle morphologies were characterized using 
LVEM. Nanoparticles were spherical and had an average diameter of about 125 nm. 
These nanoparticles were synthesized using microfluidic technology and the image was 
taken by the author.  
 Characterization of therapeutic nanoparticles is necessary to determine their 
functional use. Use in drug delivery methods is the most common application for these 
nanoparticles; however, they are only useful if they meet certain specifications of size 
and stability. Size measurements are effectively completed using DLS or NTA; the 
largest difference between these two methods is their detectors, which are a 
photomultiplier tube and microscope, respectively. Stability is determined by measuring 
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particles’ electrophoretic mobility and relating it to their zeta potential, a clear indicator 
of nanoparticle stability. ELS is a proven method for zeta potential measurements. 
Morphological characterization is done primarily by TEM; LVEM is becoming more 
reliable, but operates on the same principles as TEM.  
Biotechnology across Disciplines  
 Scientific contributions are primarily made from chemical, materials, and 
biomolecular engineering; however, mechanical and electrical engineers have also 
developed new technologies to this always increasing field of study. Engineering 
principles allowed the development of controlled release mechanisms, as well as 
instrumentation design. Characterization of drug delivery materials may involve 
mechanical stability considerations, depending on the target function of the material. For 
example, polyethylene glycol (PEG) hydrogels coated neural implants have been shown 
to effectively reduce scarring of glial cells; however, the mechanical stress between the 
implant and glial cells is important to neural functionality (Spencer et al. 2017). The 
stress, in this instance, was evaluated using atomic force microscopy and Hertzian 
analysis, which is a mathematical technique used to evaluate contact stress (Spencer et al. 
2017). Electrical engineering principles have been key in the design of new medical 
devices aimed at drug delivery. For applications to the gastrointestinal (GI) tract diseases 
or infections, the patient ingests the device; this device resides transiently in the patient 
while releasing drug until it is passed (Zhang, S et al. 2017). Since these electronic 
devices are continuously turned on, they may run out of power. A potential solution to 
this problem is wireless charging (Abid, A. et al. 2017). By focusing an electromagnetic 
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field on the device, the device can be recharged via wireless power coupling (Abid, A. et 
al. 2017). These engineering principles and approaches would likely not have developed 
from the perspective of a pure biologist or chemist and imply the necessity and 
importance of engineering collaboration in biotechnology development. Based on the 
extensive advances made by both scientists and engineers, a multi-disciplinary approach 
to solving drug-delivery problems is more effective than a one dimensional approach. 
Scientists that understand the system in question will often work with engineers to design 
an effective delivery and targeting mechanism. This expansion of health sciences into 
engineering has greatly advanced technology and has also increased the economic impact 
by the inclusion of more STEM fields. 
Economic Impact 
 The biotechnology industry affects nearly every facet of modern life. In total, the 
biotech industry makes up 1.67% of the United States GDP, which is equivalent to $324 
billion (Carlson 2016). While only a small percentage of the GDP, this sector is rapidly 
expanding at rates exceeding 10% since 2006 (Carlson 2016). Drug delivery technology 
for cancer treatment research and development alone made up $4.31B of US GDP in 
2016 and was estimated to grow 22.9% by 2025, according to a Grandview Research 
study. The instrumentation sector, although smaller than drug delivery, contributed 
$314.3M in 2017; it was predicted to grow by 5.2% to $405.1M by 2022 (Markets and 
Markets). This rapid growth should be an indication to investors that biotech has potential 
for profitability both now and in the future. The drug delivery and instrumentation growth 
should be regarded as especially important as the main thrusts of biotech research heavily 
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involve both of these fields. Health science biotech companies are not limited to large, 
publicly traded pharmacy companies such as Johnson & Johnson or Pfizer, but 
incorporates many start-up companies and mid-size businesses. While there is no funding 
shortage for big pharmaceutical companies, money is often an issue for start-up 
companies. Biotech startups, on many occasions, begin from university sponsored 
research. The number of startups originating from academia in the United States has 
increased from 61 in 2014 to 76 in 2016 (Huggett 2015, 2017). This increase further 
indicates the growth of the biotech sector. Although the success of these new companies 
has not been determined, biotech startups typically have a low success rate. Low success 
rates can be attributed to long research periods (8-12 years) and unpredictable results of 
this research and development process (Tsai, Erikson 2006). Additionally, large amounts 
of federal regulation may contribute to inhibiting startups’ success. If a new treatment 
does not fit the Federal Drug Administration’s (FDA) risk policy, the treatment will not 
be approved. While some regulation is beneficial to ensure drugs that are more 
detrimental do not reach the market. Funding for these start-ups is attained either through 
venture capitalist (VC) funding, angel investors, or research grants. While it is not 
necessary to repay research grants, they are highly competitive and it is difficult for a 
grant proposal to be accepted. VC funding and angel investors are different than grants as 
they require a share of the profit since they become partners with the founders. VC are 
investors that target early-stage companies.  
 Venture capitalists provide funding to high-growth companies. A high-growth 
company is one that has great potential to quickly generate profit or is currently 
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accelerating its rate of return. Because of their high rate of return, VC firms are attracted 
to these types of companies; however, high-growth companies, like biotech startups, are 
riskier investments. There is potential for a large return, but the risk of losing money is 
also greater. Technology company investments, in general, are particularly uncertain due 
to substantial research and development (R&D) dependence (Gompers 2001). If the new 
technology is not developed into a profitable product, money is lost. VC funding, while 
not explicitly limited to geography, is heavily influenced by company location (Gompers 
2001). Location considerations are important due to travel costs and area-familiarity 
(Fritsch 2008). These two factors are reasons why VC hubs, such as Silicon Valley and 
Boston, are so popular for startup companies. Another reason why VC firms invest 
locally is because startups require a large time-investment (Alvarez-Garrido 2014). It 
would be much harder for venture capital firms and funded companies to actively engage 
with each other over large distances. While funding may be more competitive in these 
locations, there are also more VC firms to use. VC firms may be either independently or 
corporately owned (Alvarez-Garrido 2014).  
 Apart from difference in ownership structure, these VC firms are different in their 
investment approach and return rates (Alvarez-Garrido 2014). Independent VC firms are 
the traditional, historical version of VC. These firms are privately owned and have 
company partners or associates who make investments. These partners are usually well-
versed in investment strategies and the targeted industry (Alvarez-Garrido 2014). For 
example, a well-qualified partner or associate at a biotechnology-focused VC firm would 
be someone who has experience investing with life-science technologies. An ideal 
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candidate could also be a biology, biochemistry, chemistry, or biomedical engineering 
PhD who has entrepreneurial experience. Venture capitalists provide funding in exchange 
for company equity. A typical equity rate is around 20% (Fried 1998). Coinciding with 
long R&D periods for biotech companies, VC firms usually stay involved with biotech 
companies for 7-12 years (Alvarez-Garrido 2014). This long involvement is a large risk 
for venture capitalists as it represents an extended period of making minimal or no 
returns. Because of the long investment timeline of the biotech industry, the VC 
investment landscape has been altered. Traditional VC investment strategies have 
changed with the growth of the biotech industry; in many cases, independent VC has 
completely been eliminated (Ford, Nelsen 2013).  
 Lack of VC success is the largest contributor to this trend (Ford, Nelsen 2013). 
Long-investment timelines may have also caused a shift from independent VC firms to 
corporately sponsored funding. Pharmaceutical and larger biotech companies two 
examples of corporate backed VC. Large pharmaceutical companies provide research and 
development funding for small companies in the form of a licensing agreement (Ford, 
Nielsen 2013). Although the company is not objectively any more stable, there is overall 
less investment risk for the corporate VC. While these smaller companies operate 
autonomously in their normal day to day operations, the product is sold under the 
pharmaceutical company’s product line. One motivation for this strategy is the reduction 
of in-house research funding by pharmaceutical companies; by licensing new innovations 
from startups, larger companies may end up saving money long-term (Ford, Nielsen 
2013). Startups also gain access to the larger company’s sales pipeline and contacts 
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(Alvarez-Garrido 2014). By utilizing these connections, the drug becomes widespread 
more easily. Angel investors are another avenue through which startup companies can 
attain funding. These investors are established businesspersons that may have a close 
connection with the startup owners or the geographical location of the business 
(Morrissette 2007).  
 Early-stage biotech companies should seek out funding from angel investors 
because of their heavy involvement with the company and their more relaxed timeline, as 
opposed to VC. Angel investors typically invest early in a company’s lifetime. Being 
involved in a company’s beginnings stages allows the angels to maintain a more hands-
on role as well as being able to shape the future of the company easier. A hands-on 
mentality of the angel investor is most likely due to his or her business background. 
These investors are typically successful and are entrepreneurs themselves (Morrissette 
2007). This early, heavy involvement, by nature, requires a close relationship with 
company executives. The angel investor can be more impactful within the company if he 
or she is involved when the company is in its infancy (Ramadani 2012). Because of the 
close relationship between angel investors and executives, the entrepreneur’s personality 
and drive are large factors in angel investing criteria (Sudek 2006). These criteria are 
intuitive since people who get along are more likely to work together better than those 
who do not. While the entrepreneur’s profile is important for venture capital investment, 
it is perhaps even more important for an angel since he or she takes a more involved 
company role. Another difference between angel investors and VC is the investment size. 
Angels typically invest amounts less than $100,000, while VC invest $4 million; this 
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difference is attributed to the financial source (Morrissette 2007). VC firms use money 
they have gained from many sources, but angels use their own money. Since angels are 
investing their own money, it is understandable why there is a disparity between the 
average amount of funding provided by VC and angels. Angel investors and VC also 
have different investment timelines. Venture capitalists want to minimize their company-
involvement time. This desire to reduce their time-commitment is so they can transition 
to new opportunities (Morrissette 2007). It also minimizes the risk of losing the 
investment. Angels’ investment timeline is more flexible and would probably be longer 
than VC investors (Fenstel 2011). While VC and angel investors require a return on their 
investments, research grants provide funds for research groups or companies without any 
equity.  
 Research grants are often federally funded. Agencies that award grants are the 
National Institute of Health (NIH) and the National Science Foundation (NSF). The NSF 
typically awards grants to non-biomedical investigators. The NIH is involved in 
biomedical research, ranging from basic science to translational medicine, as well as 
biomedical engineering. In 2018, the NIH provided nearly $21B in research funding; this 
funding includes research expenditures and staff and facility support (NIH 2018). While 
the NIH does not have a shortage of funding, grants are highly competitive; many 
research teams apply for a limited amount of money. The grant-awarding mechanism also 
plays into how competitive grants are. Once a grant is given approval status, it is ranked 
among other approved grants. The NIH then awards money in ranked order; however, 
since the NIH does not have funding for all research groups, the agency awards money 
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until it runs out. Two NIH research grants that startups should target are Small Business 
Technology Transfer (STTR) or Small Business Innovation Research (SBIR) grants.  
 STTR grants were started in 1994 as a way to increase technological advancement 
and economic activity from federal, university, and non-profit sponsored research (Baron 
1993). By funding high-growth companies or technology with great potential, the United 
States would become economically more competitive. This grant highlights research that 
could be spun-off into a new company with large potential for success (Baron 1993). 
These grants also aim to bridge a divide between profit-driven corporate research and 
innovation-driven university research (Ford 2008). SBIR grants have a similar motivation 
as STTR’s, but focus on women and minority researchers. The first SBIR program was 
started in 1977 at the NSF but later spread to other government agencies such as the 
Department of Defense, Defense Advanced Research Program Agency, and NIH 
(Audretsch 2002, Link 2008). This targeting towards underrepresented groups in science 
was initially implemented because of apparent discrimination towards women 
investigators (Link 2008). Although there may have been some preference towards men 
in the past, these grants should help eliminate any non-merit based bias that occurs. 
Statistical analysis has shown that female owned companies exhibit a similar level of 
commercialization for their product compared to male owned companies (Link 2008). 
This data supports the alleged bias towards women in grant funding. Both STTR and 
SBIR grants should be attractive to early-stage biotech companies looking for funding. 
Biotech companies involved in drug delivery and nanomedicine is not only a large 
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portion of the health sciences field, but it also greatly impacts many engineering 
disciplines as well.  
 Therapeutic delivery technology is a central focus in biomedical science related 
areas. These technologies include treatment mechanisms, as well as the delivery vehicle. 
The goal of these technologies is to produce more effective treatments for diseases such 
as cancer, atrial fibrillation, and numerous genetically based diseases (Serna 2018, 
O’Quinn 2018, Beitelshees 2017). Gene therapy, protein therapy, and drug delivery are 
three treatment methods currently being investigated. Gene therapy restores mutated 
genes to a healthy condition. By fixing the mutated gene, healthy gene products will be 
produced and disease symptoms will be mitigated. Protein therapy involves the delivery 
of a peptide-based therapeutic in order to treat a disease. Drug delivery technologies 
introduce non-peptide-based therapeutics into the patient. Just as important to the 
treatment as the drug is the delivery vehicle. Currently popular and effective vehicles are 
viral vectors, liposomal, or polymeric nanoparticles; these nanoparticles promote 
enhanced therapeutic payload. Due to the microscopic qualities of these particles, 
characterization instrumentation such as DLS, ELS, TEM, and SEM are necessary to 
determine their physical properties. Therapeutic delivery technology is not only a large 
research interest within the scientific community but is also a significant economic 
component. Economic impacts from this sector range from small startups to large biotech 
and pharmaceutical companies. These large monetary investments, as well as scientific 
interest, are key signs that biotechnology will be the focus of biomedical research and 
entrepreneurship for the foreseeable future.   
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